China Approves World’s First Bispecific IO Drug Amid PD-1/L1 Glut

But Competition Looms

 
• By Dexter Jie Yan
  
bispecific antibody
Beyond massive investment in PD-1/L1 programs, Chinese firms are now gearing up for bispecific antibodies • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia